Hudson Bay Capital Management
ORMP icon

Hudson Bay Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Hudson Bay Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4K Sell
10,265
-41,405
-80% -$165K ﹤0.01% 1230
2026
Q1 		$176K Buy
+51,670
New +$175K ﹤0.01% 1120

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hudson Bay Capital Management's ORMP Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Oramed Pharmaceuticals (ORMP) stake by 80% in Q2 2026, selling an estimated $165K and leaving 10,265 shares worth $49.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1230.

Hudson Bay Capital Management first reported a position in ORMP in Q1 2026 and has held it in 2 quarters since. The position peaked at $176K in Q1 2026. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Hudson Bay Capital Management held 10,265 shares of Oramed Pharmaceuticals worth $49.4K as of Q2 2026.
  • Hudson Bay Capital Management sold 41,405 Oramed Pharmaceuticals shares in Q2 2026, an estimated $165K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #1230 holding.
  • Hudson Bay Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Hudson Bay Capital Management's Oramed Pharmaceuticals position peaked at $176K in Q1 2026.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.